29 completed. 29 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 29 | Completed 29 |
| Phase 2 | 2 | Completed 2 |
Follow Interferon-alpha: new trials by email Literature Review of Interferon-alpha trials Research Report on Interferon-alpha
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; Interferon alfa, Selinexor, Lenzilumab - Cancer, Covid19 | Phase 3 | Completed | Peter MacCallum Cancer Centre, Australia | 441 | 2020-12-17 | 2023-08-24 |
| ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma ABR-217620/naptumomab estafenatox, IFN-alpha - Renal Cell Carcinoma | Phase 2 / Phase 3 | Completed | Active Biotech AB | 526 | 2007-01-01 | 2015-07-22 |
| SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Interferon-alfa, SU011248 - Carcinoma, Renal Cell | Phase 3 | Completed | Pfizer | 750 | 2004-08-01 | 2010-01-26 |
| Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer recombinant interferon alfa, vitamin E, isotretinoin - Head and Neck Cancer | Phase 3 | Completed | Eastern Cooperative Oncology Group | 2003-11-26 | 2023-06-15 | |
| Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) bevacizumab, recombinant interferon alfa - Kidney Cancer | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 732 | 2003-10-01 | 2016-07-06 |
| Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma Interferon Alfa, CCI-779, Interferon Alfa and CCI-779 - Carcinoma, Renal Cell, Kidney Neoplasms | Phase 3 | Completed | Pfizer | 626 | 2003-07-01 | 2012-10-25 |
| Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) thalidomide, interferon alpha - Multiple Myeloma | Phase 3 | Completed | Università Politecnica delle Marche | 103 | 2003-06-01 | 2008-03-12 |
| Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer aldesleukin, recombinant interferon alfa, fluorouracil - Kidney Cancer | Phase 3 | Completed | Medical Research Council | 670 | 2002-07-01 | 2013-12-19 |
| Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia recombinant interferon alfa, cytarabine, hydroxyurea - Leukemia | Phase 3 | Completed | Heidelberg University | 1551 | 2002-06-01 | 2018-05-03 |
| Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer recombinant interferon alfa, thalidomide - Kidney Cancer | Phase 3 | Completed | Eastern Cooperative Oncology Group | 2000-10-01 | 2009-02-05 | |
| S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma interleukin-2, filgrastim, interferon alfa - Melanoma (Skin) | Phase 3 | Completed | SWOG Cancer Research Network | 432 | 2000-08-01 | 2015-03-25 |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C) - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 1106 | 2000-06-01 | 2013-10-14 |
| STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia recombinant interferon alfa, cytarabine, imatinib mesylate - Leukemia | Phase 3 | Completed | Novartis | 2000-06-01 | 2013-01-03 | |
| Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis Interleukin-2, Interferon alfa, medroxyprogesterone acetate - Metastatic Renal Cell Carcinoma | Phase 3 | Completed | Centre Leon Berard | 456 | 1999-12-01 | 2006-02-16 |
| Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis recombinant interferon alfa, lymphangiography, Observation - Melanoma (Skin) | Phase 3 | Completed | University of Alabama at Birmingham | 3000 | 1999-10-01 | 2014-01-20 |
| Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin recombinant interferon alfa, radiation therapy - Melanoma (Skin) | Phase 3 | Completed | Eastern Cooperative Oncology Group | 167 | 1999-03-29 | 2023-06-22 |
| High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma interferon alfa-2b, observation - Melanoma (Skin) | Phase 3 | Completed | ECOG-ACRIN Cancer Research Group | 1150 | 1999-03-25 | 2026-09-29 |
| Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer aldesleukin, recombinant interferon alfa, fluorouracil - Kidney Cancer | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 96 | 1998-02-01 | 2012-09-24 |
| Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia filgrastim, recombinant interferon alfa, busulfan - Leukemia | Phase 3 | Completed | Eastern Cooperative Oncology Group | 744 | 1997-11-20 | 2023-06-22 |
| Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma aldesleukin, filgrastim, recombinant interferon alfa - Melanoma (Skin) | Phase 3 | Completed | Eastern Cooperative Oncology Group | 482 | 1997-11-13 | 2023-06-22 |
Showing 20 of 29. Sign in to see all of them.
Carcinoma, Renal Cell (10) · Kidney Neoplasms (7) · Melanoma (7) · Leukemia (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Chronic-Phase (3) · Multiple Myeloma (2) · COVID-19 (1) · Communicable Diseases (1) · Head and Neck Neoplasms (1) · Hepatitis C (1) · Immune System Diseases (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1)
Eastern Cooperative Oncology Group (5) · Centre Leon Berard (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · M.D. Anderson Cancer Center (2) · Pfizer (2) · SWOG Cancer Research Network (2) · Active Biotech AB (1) · Alliance for Clinical Trials in Oncology (1) · ECOG-ACRIN Cancer Research Group (1) · Heidelberg University (1) · Institute of Cancer Research, United Kingdom (1) · Medical Research Council (1) · National Center for Research Resources (NCRR) (1) · National University Hospital, Singapore (1) · Novartis (1)
United States (16) · Australia (8) · United Kingdom (8) · Germany (6) · Italy (6) · Canada (5) · Netherlands (5) · Belgium (4) · Russia (4) · France (3) · Hungary (3) · South Africa (3) · Spain (3) · Switzerland (3) · Turkey (Türkiye) (3)
Lawrence E. Flaherty, MD (3) · Alberto S. Pappo, MD (2) · John M. Kirkwood, MD (2) · Michael B. Atkins, MD (2) · Agop Y. Bedikian, MD (1) · Anna S. F. Lok (1) · Barry W. Hancock, MD (1) · Bart Barlogie, MD (1) · Brian I. Rini, MD (1) · David M. Gustin, MD (1) · Dong M. Shin, MD (1) · Frank Haluska, MD, PhD (1) · Hein van Poppel, MD, PhD (1) · Hillard M. Lazarus, MD (1)
PMID 37146227, PMID 25577718, PMID 27238653, PMID 28273028, PMID 28410911, PMID 12637609, PMID 14665609, PMID 15102658, PMID 15961764, PMID 16432076, PMID 17151364, PMID 17215529, PMID 17538086, PMID 18256322, PMID 18794104, PMID 18936475, PMID 19001327, PMID 19117345, PMID 19430405, PMID 19648168, PMID 19965667, PMID 20104222, PMID 20142590, PMID 20153039, PMID 20368558, PMID 20679528, PMID 21163569, PMID 21422420, PMID 22689675, PMID 23515925, PMID 23620574, PMID 24162333, PMID 24297946, PMID 24622328, PMID 24658964, PMID 24837466, PMID 24859364, PMID 25332243, PMID 25465231, PMID 25669986, PMID 25918346, PMID 29479070, PMID 29853320, PMID 34473343, PMID 34965953, PMID 40874769
P30CA016672 (2), U10CA032102 (2), U10CA023318 (1), U10CA031946 (1)